BSE · 540359
Parmax Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹12 Cr with net profit ₹-4 Cr — a -34.21% net margin, versus -7.41% the period before.
Shareholding
As of 2026-09-30
- Promoter64.66%
- Public35.34%
2,151 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 5.98× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0 · ESM · ESM 2. Trading may carry price bands, periodic call auction or higher margins.
- 52-week range spans 5.98× (₹22.6 to ₹135.05) — an unusually wide band.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #21 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,46,965 Cr | 82.89 | 14.73 | 15.32% | 26.05% |
| Neuland Laboratories Ltd. | ₹29,105 Cr | 58.47 | 15.53 | 19.42% | 20.99% |
| Acutaas Chemicals Limited | ₹27,164 Cr | 70.34 | 16.43 | 21.54% | 26.42% |
| Jubilant Pharmova Ltd. | ₹16,131 Cr | 41.57 | 2.27 | 5.62% | 4.11% |
| Aarti Drugs Ltd. | ₹3,913 Cr | 20.31 | 2.53 | 12.58% | 7.14% |
| SMS Pharmaceuticals Ltd. | ₹3,840 Cr | 37.52 | 4.89 | 12.98% | 11.41% |
| Hikal Limited | ₹2,786 Cr | 65.69 | 2.32 | 3.03% | -1.96% |
| Beta Drugs Limited | ₹2,318 Cr | 50.85 | 9.43 | 16.95% | 11.11% |
| NGL Fine Chem Limited | ₹1,656 Cr | 28.96 | 5.03 | 14.62% | 10.67% |
| Fermenta Biotech Ltd. | ₹1,369 Cr | 25 | 3.37 | 17.67% | 11.68% |
| Parmax Pharma Limited(this company) | ₹93 Cr | — | 20.22 | 67.65% | -6.47% |
AI analysis
AI-generated · google/gemini-2.5-flashParmax Pharma Limited is listed on the Indian markets with a market capitalization of Rs 39 Cr. The company reported a revenue of Rs 28.24 Cr and a net profit margin of -34.27%.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no traditional debt.
Negatives
- −The company has consistently reported negative net profits, with a loss of Rs -2.09 Cr in March 2025.
- −The profit margin is negative at -34.27%.
- −Return on capital employed (ROCE) is -85.76%.
- −Book value per share is negative at -18.33.
- −The company is under regulatory surveillance (GSM and ESM).
Financial performance
Parmax Pharma Limited's annual revenue has fluctuated in recent years. Revenue decreased from Rs 26.29 Cr in March 2021 to Rs 11.10 Cr in March 2024, before increasing to Rs 28.24 Cr in March 2025. The company has reported negative net profits for the last three financial years, with a loss of Rs -2.09 Cr in March 2025.
Profitability & Returns
The company's profitability has been negative, with a profit margin of -34.27%. Return on capital employed (ROCE) was -85.76% in the latest period. While Return on Equity (ROE) was 67.65%, this figure should be considered in conjunction with a negative book value of -18.33.
Balance Sheet
Parmax Pharma Limited has a book value per share of -18.33, indicating that liabilities exceed assets. The debt-to-equity ratio is 0, suggesting the company has no traditional debt. Net profit per share (EPS) declined significantly from 2.02 in March 2021 to -5.6 in March 2025.
Ownership & Pledges
Public shareholding stands at 69.19%. There are no shares pledged by the promoters, with promoter pledge at 0%.
Regulatory & Surveillance
Parmax Pharma Limited is currently under surveillance by regulatory authorities. The company is subject to both GSM and ESM frameworks, as indicated by its inclusion in 'GSM · GSM 0 · ESM · ESM 2' surveillance measures.
Data as of — price: 2026-09-17 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.